With $AGN.C’s latest topline data release, things are starting to look good for the company. I want to especially focus on the IPF trial as it recently hit the phase 2 co-primary endpoint here. It’s estimated that around 207,000 people suffer from idiopathic pulmonary fibrosis (IPF), with 58,000 more cases diagnosed each year in the US alone. Now, there’s currently a duopoly in the market with only 2 approved prescriptions to treat the disease costing upwards of $100,000. Meaning there’s a multibillion-dollar market waiting to be disrupted by $AGN.C’s Ifenprodil medication.
- Of the 20 patients who enrolled, 13 (65%) had improved forced vital capacity over the 12-week treatment period.
- This reached statistical significance over the placebo trials of 40%, meaning that the Ifenprodil was both safe and effective within this trial.
- With plans to file for a Phase 2b study, the study will include multiple arms, multiple doses, would be placebo-controlled and would be double-blinded and randomized to increase transparency and efficacy.
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-hits-co-primary-120000001.html
Overall, considering that they’ve reached statistical significance with only a $5M market cap (and a recently placed $25 price target), there could be room for stock growth in the near future as the company continues to conduct research for drug repurposing. Keep a close eye out for any future results as the company is working hard on the research trials.